Reducing radiation for head and neck cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on patients with head and neck squamous cell carcinoma (HNSCC) who have positive lymph nodes on one side of the neck. It evaluates the use of sentinel lymph node mapping to tailor radiation treatment, potentially reducing the volume and dose of radiation delivered to the contralateral neck. By identifying which nodes require irradiation, the study aims to minimize the risk of severe side effects associated with excessive radiation. The approach is based on previous findings that suggest individualized treatment can lead to better outcomes.

Why it matters

Who can join: the full rules

Inclusion criteria

1. Written informed consent given according to ICH/GCP and national/local regulations must be obtained prior to any screening procedures.
2. World Health Organization (WHO) performance status 0-1.
3. Age ≥ 18 years.
4. Patients with a pathologically proven invasive HNSCC, including oral cavity, oropharynx (independently of HPV status), larynx or hypopharynx.
5. Decision by Multidisciplinary Tumor Board of primary treatment with radical radiotherapy with or without concurrent chemotherapy (according to the local guidelines).
6. Baseline imaging of the neck:

   1. ≤ 2.5 mm slices CT with iodine injection (independently or during the FDG-PET/CT examination IF acquired in normal diagnostic conditions, i.e. arms along the thorax with diagnostic quality);
   2. MRI not mandatory but allowed, performed according to centres guidelines;
   3. FDG-PET/CT.
7. Tumor characteristics:

   1. cT-classification (8th TNM staging): T1(except T1 of glottis)-T4a (or, for p16+ oropharyngeal tumors classified cT4, if criteria are compatible with cT4a-stage of p16- tumors).
   2. cN-classification (8th TNM staging), as assessed by iodine contrasted CT (or MRI) and FDG-PET:

      * i. mandatorily cN0 contralaterally to the primary tumor (or on one side of the neck for midline primary tumors):

        * 1\. smallest diameter \< 5 mm in retropharyngeal level (VIIa);
        * 2\. smallest diameter of Küttner node (level IIa) \< 12 mm;
        * 3\. smallest diameter \< 10 mm or sum of smallest and largest diameters \< 17 mm in any other level;
        * 4\. no central necrosis ;
        * 5\. maximal standardized uptake value (SUVmax) ≤ 2.2;
        * 6\. in dubious cases (typically 2.2 \< SUVmax \< 4.5 and inconclusive CT or MRI), US-guided FNAC may be required to exclude positive node contralaterally.
      * ii. ipsilaterally positive (if any of the above mentioned criteria is met), i.e. cN1, cN2a, cN2b, ipsilateral cN3b; or cN1 for oropharyngeal p16+ tumors.
   3. No distant metastasis.

Exclusion criteria

1. Patient has history of:

   1. radiotherapy or surgery in the neck with potential impact on lymphatic drainage ("violated neck");
   2. cancer in the last five years (excluding skin basal cell carcinoma, in situ cervix carcinoma and T1 of glottis or lip, completely chirurgically resected (R0) without intervention disturbing cervical lymph drainage);
   3. Absolute contra-indication to iodine contrast injection, even after proper cortisone and cetirizine pre-medication.
2. HNSCC from nose, sinuses, oesophagus, salivary glands or nasopharynx.
3. Non-HNSCC histology.
4. Positive contralateral neck by node size or positive US-FNAC in dubious nodes.
5. Synchronous second malignancy.
6. Distant metastasis.
7. Tumor crossing the midline without contralateral mapping after 99mTc-nanocolloïd injection.
8. Tumor too large to be safely injected, as deemed by the surgeon. In case of doubt, contact may always be taken with the national coordinating investigator to discuss the situation and take a final decision.
9. Any psychological disorder or familial, sociological or geographical condition which, in the investigator's opinion, might jeopardise participant's safety or compliance with the protocol.
10. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method.

Highly effective methods of birth control are defined as those, alone or in combination, that result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as implants, injectables, combined oral contraceptives, some IUDs, true sexual abstinence (i.e. refraining from heterosexual intercourse during the entire period of risk associated with the Trial treatments) or vasectomised partner.

Where it's running

• Zol
  Genk, Limburg, Belgium Recruiting
• Jessa Ziekenhuis
  Hasselt, Limburg, Belgium Recruiting
• OLV Aalst
  Aalst, Belgium Recruiting
• UCL Saint-Luc
  Brussels, Belgium Recruiting
• Institute Jules Bordet
  Brussels, Belgium Recruiting
• University Hospital Gent
  Ghent, Belgium Recruiting

Study contacts

• Principal investigator: Jean-François Daisne, Prof. Dr. — Universitaire Ziekenhuizen KU Leuven
• Study coordinator: Jean-François Daisne, MD, PhD
• Email: jean-francois.daisne@uzleuven.be
• Phone: +32-16-34-76-00

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TMV vaccine alone or with toripalimab for recurrent head and neck cancer

  This study tests a personalized TMV vaccine, alone and with toripalimab, in adults whose head and neck cancer has returned and is planning salvage surgery.

  Recruiting Phase 1 Metaclipse Therapeutics Corporation · Houston, Texas · NCT07898124

• Iparomlimab plus tuvonralimab, with or without chemotherapy, for second-line and later recurrent or metastatic head and neck squamous cell carcinoma

  This will try whether combining two antibodies, iparomlimab and tuvonralimab, with or without chemotherapy helps people with recurrent or metastatic head and neck squamous cell carcinoma whose cancer progressed after at least one systemic treatment.

  Recruiting The Second Affiliated Hospital of Hainan Medical University · Haikou, Hainan · NCT07546383

• Cetuximab with PD-1 therapy plus chemotherapy vs PD-1 therapy with chemotherapy for recurrent/metastatic head and neck cancer

  This trial tests whether adding cetuximab to a PD-1 inhibitor plus chemotherapy helps people with recurrent or metastatic head and neck squamous cell cancer who aren’t candidates for curative treatment.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality and 1 other locations · NCT07509099

• Neoadjuvant CADI-05 with pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma

  This will test whether adding weekly CADI-05 skin injections to pembrolizumab before surgery helps adults with resectable locally advanced head and neck squamous cell cancer.

  Recruiting at 2 sites Phase 1 Fox Chase Cancer Center · Philadelphia, Pennsylvania and 1 other locations · NCT07455032

• 5-Fluorouracil Response and Optimization (FROST)

  This trial will test two different dosing schedules of 5‑fluorouracil as second-line-or-later treatment for people with recurrent or metastatic head and neck squamous cell carcinoma who have already had platinum and PD‑1 inhibitor therapy.

  Recruiting Phase 2 Washington University School of Medicine · St Louis, Missouri · NCT07419464

• Amivantamab added to pembrolizumab and platinum chemotherapy versus pembrolizumab with platinum/5‑FU for recurrent/metastatic head and neck squamous cell carcinoma

  This trial will see if adding amivantamab to pembrolizumab and platinum‑based chemotherapy helps adults with recurrent or metastatic head and neck squamous cell carcinoma who have not yet had systemic treatment in the metastatic setting.

  Recruiting at 205 sites Phase 3 Janssen Research & Development, LLC · Chandler, Arizona and 204 other locations · NCT07276399

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.